Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Researchers in New Zealand, the USA and Germany have made a discovery about the bacteria that causes tuberculosis (TB) that could pave the way to new drugs to fight the disease.
The study, published in the journal, Proceedings of the National Academy of Sciences (PNAS), aimed to understand why mycobacteria (the family of bacteria that includes the species that causes TB) can survive for long periods without, or with a very low supply of, oxygen.
The researchers found that, the bacteria that causes TB seems to use hydrogen as an energy source rather than oxygen if there is little or no oxygen available..
They are now researching whether they can target the cells by starving them of their supply of hydrogen.
If successful, this method could open up new options for the treatment of inactive TB infections, which affect around one-third of the world’s population.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79